Bonus Biogroup - Asset Resilience Ratio
Bonus Biogroup (BONS) has an Asset Resilience Ratio of 10.04% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BONS working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2015)
This chart shows how Bonus Biogroup's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BONS total assets.
Liquid Assets Composition Over Time
This chart breaks down Bonus Biogroup's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BONS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA3.90 Million | 10.04% |
| Total Liquid Assets | ILA3.90 Million | 10.04% |
Asset Resilience Insights
- Moderate Liquidity: Bonus Biogroup has 10.04% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bonus Biogroup Industry Peers by Asset Resilience Ratio
Compare Bonus Biogroup's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Bonus Biogroup (2008–2015)
The table below shows the annual Asset Resilience Ratio data for Bonus Biogroup.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 1.88% | ILA108.00K ≈ $289.54 |
ILA5.76 Million ≈ $15.43K |
-20.23pp |
| 2014-12-31 | 22.11% | ILA1.00 Million ≈ $2.68K |
ILA4.52 Million ≈ $12.13K |
-42.61pp |
| 2013-12-31 | 64.72% | ILA5.28 Million ≈ $14.15K |
ILA8.16 Million ≈ $21.87K |
-12.06pp |
| 2012-12-31 | 76.78% | ILA6.80 Million ≈ $18.22K |
ILA8.85 Million ≈ $23.73K |
+71.44pp |
| 2010-12-31 | 5.34% | ILA324.00K ≈ $868.63 |
ILA6.07 Million ≈ $16.28K |
+0.43pp |
| 2009-12-31 | 4.90% | ILA2.42 Million ≈ $6.49K |
ILA49.39 Million ≈ $132.40K |
+0.78pp |
| 2008-12-31 | 4.13% | ILA2.10 Million ≈ $5.62K |
ILA50.81 Million ≈ $136.21K |
-- |
About Bonus Biogroup
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more